Studies Evaluating REVLIMID(R) (Lenalidomide) in Lymphoma Presented at ASHMarketWatchIn the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction i…
|
Studies Evaluating REVLIMID® (Lenalidomide) in Lymphoma Presented at ASH
Business Wire (press release) In the first study, Dr. Nishitha M. Reddy evaluated whether maintenance treatment with lenalidomide plus rituximab would result in a clinically significant reduction in relapse rates when compared with lenalidomide alone. DLBCL patients with an … |
|
Positive Data on Infinity Pharma Candidate
Zacks.com The study will evaluate the safety and efficacy of IPI-145 in iNHL patients whose disease is refractory to radioimmunotherapy or to both Roche/Biogen Idec Inc.’s (RHHBY)/(BIIB – Analyst Report) Rituxan (rituximab) and chemotherapy and who have … Infinity Reports Updated Phase 1 Data of IPI-145 in Indolent Non-Hodgkin …Business Wire (press release) Infinity Reports Preclinical Data at ASH Annual Meeting in Diffuse Large B …MarketWatch |
OncLiveOfatumumab Improves Response Rates, PFS in Elderly/Unfit Patients With CLLOncLiveIn older CLL patients who are unfit for the gold-standard therapy of fludarabine-cyclophosphamide-rituximab, chlorambucil using a variety of dosing schedules remain…
Biosimilar Opportunities in an Evolving MarketPR Web (press release)… clinical trials in recent months. For example, in February 2013, Amgen announced plans to launch a portfolio of six new biosimilars beginning in 2017: adalimumab, infliximab, bevac…
Combo Active in Pretreated, Poor-Risk CLLMedPage TodayNEW ORLEANS — Patients with poor-risk chronic lymphocytic leukemia had significant improvement in survival when treated with an investigational small-molecule inhibitor plus rituximab, results of a…
Novel Targeted Therapies in CLL Might Expand Treatment OptionsMedscapeOther studies with the novel agent in CLL are underway, including a phase 2 monotherapy study in patients with relapsed CLL and 17p deletions and combination studies with rituximab o…
Seattle Genetics Highlights ADCETRIS(R) (Brentuximab Vedotin) Phase 2 …MarketWatchThe phase 2 clinical trial presented at ASH has been expanded to include a treatment arm to assess the activity and tolerability of ADCETRIS in combination with Rituxan…
Emergent Bio (EBS) Issues Encouraging Update on TRU-016 Phase 1b in CLL …StreetInsider.com (subscription)Emergent Biosolutions (NYSE: EBS) announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy o…
|
Emergent BioSolutions’ Otlertuzumab (TRU-016) Shows Positive Results in …
Wall Street Journal Emergent BioSolutions Inc. (NYSE: EBS) today announced preliminary results from a Phase 1b single-arm, open-label study evaluating the safety and efficacy of otlertuzumab (TRU-016) in combination with rituximab in people with previously untreated … |